Synthon has announced that it has successfully concluded the decentralised procedures for glatiramer acetate 40mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe.
Synthon received regulatory clearance in all 27 EU/EEA member states involved in the procedures. Granting of national marketing authorizations will follow in the near future.
Synthon’s 20mg/ml glatiramer acetate product has already received marketing authorisations in these European countries. As of the end of 2016, Synthon’s partners have introduced glatiramer acetate 20mg/ml in the majority of these countries.
“We are very pleased with this approval,” commented Synthon’s chief executive officer Jacques Lemmens. “It allows us to make an affordable version of the 40mg/ml dosage strength of glatiramer acetate available to MS patients in Europe.”
